文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

ARDS、肺炎与脓毒症联盟:国家危重病综合征表型分析平台的理论基础、设计与可行性

The ARDS, Pneumonia, and Sepsis Consortium: Rationale, Design, and Feasibility of a National Platform for Phenotyping Critical Illness Syndromes.
PubMed 文献 · Chest · 2026-07-13
一句话结论APS联盟前瞻性队列在<13个月内完成首1000例入组,生物样本采集率高,经专家裁定40%为ARDS、52%为肺炎、89%为脓毒症。

APS联盟表型研究是一项多中心、纵向、前瞻性、观察性队列研究,计划4年内入组4000例ARDS、肺炎或脓毒症危重成人,收集数据与生物样本以进行生物学亚型分类。首批1000例提前完成入组(<13个月),中位年龄64岁,75%使用血管加压药,50%接受有创机械通气,25%在入组4周内院内死亡。生物样本采集率高:99%血样、98%上呼吸道拭子、37%下呼吸道样本、80%尿样、65%胃肠道样本。专家裁定40%为ARDS、52%为肺炎、89%为脓毒症。该平台为危重病综合征的精准表型研究提供高质量队列。

要点

  • 首批1000例危重成人中位年龄64岁,75%使用血管加压药,50%接受有创机械通气,25%入组4周内院内死亡。
  • 生物样本采集率高:99%血样、98%上呼吸道拭子、37%下呼吸道样本、80%尿样、65%胃肠道样本。
  • 专家裁定分类:40%为ARDS、52%为肺炎、89%为脓毒症,显示综合征重叠与裁定重要性。
  • 研究计划4年内入组4000例ARDS、肺炎或脓毒症危重成人,首批1000例在<13个月内提前完成。
  • 该队列旨在将ARDS、肺炎和脓毒症细分为具有共同病理生理特征的生物学亚型,以加速治疗开发。

适用人群与场景

  • 纳入:危重成人,患有ARDS、肺炎或脓毒症,计划4年内入组4000例。
  • 首批1000例特征:中位年龄64岁,75%使用血管加压药,50%接受有创机械通气。
  • 排除人群:原文未提及。
  • 场景:多中心、纵向、前瞻性、观察性队列,非急诊/院前特定场景。

诊断标准与关键阈值

  • ARDS、肺炎、脓毒症的确认基于专家裁定(expert adjudication),首批1000例中裁定比例分别为40%、52%、89%。
  • 原文未提及具体诊断标准、评分界值或启动/停止阈值。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:多中心、纵向、前瞻性、观察性队列研究;计划入组4000例,首批1000例分析。
  • 首批1000例在<13个月内提前完成入组;中位年龄64岁,75%使用血管加压药,50%接受有创机械通气,25%入组4周内院内死亡。
  • 生物样本采集率:99%血样、98%上呼吸道拭子、37%下呼吸道样本、80%尿样、65%胃肠道样本。
  • 专家裁定:40%为ARDS、52%为肺炎、89%为脓毒症。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察性队列研究的可行性分析(首批1000例)。
  • 局限:原文未明确列出;设计上为观察性研究,首批1000例可行性结果,非干预性结论。

对床旁实践的改变

  • 该研究提供危重病综合征(ARDS、肺炎、脓毒症)前瞻性队列构建与生物样本采集的可行性数据,支持未来表型分型研究。
  • 首批1000例中75%使用血管加压药、50%接受有创机械通气、25%院内死亡,提示入组人群病情重。
  • 专家裁定显示综合征重叠常见(89%脓毒症、52%肺炎、40%ARDS),提示临床识别需综合判断。
  • 原文未提及对急诊/ICU具体治疗方案的改变。

指南或共识出处

  • ARDS, Pneumonia, and Sepsis (APS) Consortium Phenotyping Study;ClinicalTrials.gov注册号NCT06521502。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: To enhance biological understanding of ARDS, pneumonia, and sepsis and to accelerate therapeutic development in these areas, the National Institutes of Health developed the ARDS, Pneumonia, and Sepsis (APS) Consortium.

RESEARCH QUESTION: Is the APS Consortium study rapidly generating data and biospecimens from a large cohort of critically ill adults with ARDS, pneumonia, and sepsis that will facilitate phenotyping of these syndromes?

STUDY DESIGN AND METHODS: The APS Consortium Phenotyping Study is a multicenter, longitudinal, prospective, observational cohort study aimed at enrolling 4,000 critically ill adults with ARDS, pneumonia, or sepsis over 4 years. Data and biospecimens are collected to characterize many aspects of each participant's chronic health, acute illness, and long-term recovery to facilitate phenotyping, that is, subclassifying ARDS, pneumonia, and sepsis into precise biologically based subsets with shared pathophysiologic characteristics. Feasibility of the study was assessed by evaluating the first 1,000 participants in terms of recruitment pace, participant characteristics, biospecimen collection, and proportion with confirmed ARDS, pneumonia, and sepsis based on expert adjudication.

RESULTS: The first 1,000 participants were recruited ahead of schedule in < 13 months. Median age was 64 years, 75% received vasopressors, 50% received invasive mechanical ventilation, and 25% died in the hospital within 4 weeks of enrollment. Biospecimen collection rates were high, with 99% of participants with blood samples, 98% with upper respiratory swabs, 37% with lower respiratory samples, 80% with urine samples, and 65% with gastrointestinal samples. Expert adjudication resulted in 40% classified with ARDS, 52% classified with pneumonia, and 89% classified with sepsis.

INTERPRETATION: The APS Consortium Phenotyping Study is producing a cohort of critically ill adults with ARDS, pneumonia, and sepsis with high severity of disease and a rich set of data and biospecimens. The study will continue to full enrollment of 4,000 participants.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT06521502; URL: www.

CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Self WH, Calfee CS, Brown SM, et al. The ARDS, Pneumonia, and Sepsis Consortium: Rationale, Design, and Feasibility of a National Platform for Phenotyping Critical Illness Syndromes. Chest. 2026. PMID: 42442528. doi:10.1016/j.chest.2026.05.053

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。